<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583674</url>
  </required_header>
  <id_info>
    <org_study_id>20060439</org_study_id>
    <nct_id>NCT00583674</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin &amp; Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma</brief_title>
  <official_title>A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin &amp; Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This is a phase 2, randomized, double blind, placebo controlled, multi-center study to&#xD;
      estimate the improvement in progression free survival (compared to control subjects) and&#xD;
      evaluate the safety and tolerability of AMG 386 in combination with Cisplatin &amp; Capecitabine&#xD;
      in the treatment of subjects with Metastatic Gastric, Gastroesophageal Junction, or Distal&#xD;
      Esophageal Adenocarcinoma. AMG 386 is a man-made medication that is designed to stop the&#xD;
      development of blood vessels in cancer tissues. Cancer tissues rely on the development of new&#xD;
      blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to&#xD;
      grow.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>22 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 placebo</intervention_name>
    <description>AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 10mg/kg</intervention_name>
    <description>AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 386 3mg/kg</intervention_name>
    <description>AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease Related&#xD;
&#xD;
               -  Histologically or cytologically confirmed adenocarcinoma of the stomach,&#xD;
                  gastroesophageal junction or distal esophagus with metastatic disease&#xD;
&#xD;
               -  Measurable or non-measurable disease per RECIST Guidelines&#xD;
&#xD;
               -  Prior gastrectomy (total or partial) may be allowed as long as subjects can take&#xD;
                  oral medications and meet all other inclusion/exclusion criteria. Subjects may&#xD;
                  not take crushed or dissolved capecitabine via a feeding/gastrostomy tube&#xD;
&#xD;
               -  Palliative radiotherapy for metastatic esophageal or gastric cancer prior to&#xD;
                  study entry may be allowed as long as all toxicities from radiotherapy have&#xD;
                  resolved and the radiotherapy was not to the only site of known metastatic&#xD;
                  disease&#xD;
&#xD;
          -  Demographic&#xD;
&#xD;
             •18 years of age or older at the time the written informed consent is obtained&#xD;
&#xD;
          -  General&#xD;
&#xD;
               -  Able to swallow oral medication&#xD;
&#xD;
               -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Laboratory&#xD;
&#xD;
               -  Adequate organ and hematological function as evidenced by laboratory studies&#xD;
                  prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease Related&#xD;
&#xD;
               -  Prior chemotherapy for metastatic disease (1st line)&#xD;
&#xD;
               -  Less than 12 months have elapsed from completion of previous adjuvant or&#xD;
                  neoadjuvant chemotherapy or chemoradiotherapy&#xD;
&#xD;
               -  Subjects with persistent gastric outlet obstruction, complete dysphagia or&#xD;
                  feeding jejunostomy&#xD;
&#xD;
               -  Radiotherapy ≤ 14 days prior to randomization. Subjects must have recovered from&#xD;
                  all radiotherapy-related toxicities&#xD;
&#xD;
               -  Current or prior history of central nervous system metastases&#xD;
&#xD;
               -  History of arterial or deep venous thromboembolism within 12 months prior to&#xD;
                  randomization&#xD;
&#xD;
               -  History of bleeding diathesis or clinically significant bleeding within 6 months&#xD;
                  prior to randomization&#xD;
&#xD;
               -  Major surgical procedure within 28 days prior to randomization&#xD;
&#xD;
               -  Minor surgical procedure, placement of central venous access device or fine&#xD;
                  needle aspiration within 3 days prior to randomization&#xD;
&#xD;
               -  Prior malignancy except: malignancy treated with curative intent and without&#xD;
                  evidence of active disease for ≥ 3 years prior to randomization and felt to be at&#xD;
                  low risk for recurrence by treating physician, adequately treated&#xD;
                  non-melanomatous skin cancer or lentigo maligna without evidence of disease,&#xD;
                  adequately treated cervical carcinoma in situ without evidence of disease,&#xD;
                  prostatic intraepithelial neoplasia without evidence of prostate cancer&#xD;
&#xD;
               -  Prior malignancy (other than in situ cervical cancer, or basal cell cancer of the&#xD;
                  skin) unless treated with curative intent and without evidence of disease for ≥ 3&#xD;
                  years prior to randomization&#xD;
&#xD;
               -  Clinically significant cardiovascular diseases within 12 months prior to&#xD;
                  randomization&#xD;
&#xD;
               -  Presence of clinically significant non-healing wound, ulcer (including&#xD;
                  gastrointestinal) or fracture as judged by the investigator&#xD;
&#xD;
               -  Ongoing or clinically significant active infection as judged by the investigator&#xD;
&#xD;
               -  Known hypersensitivity to bacterial proteins, or any of the drugs required in&#xD;
                  this study&#xD;
&#xD;
               -  Known peripheral neuropathy ≥Grade 1&#xD;
&#xD;
               -  Known dihydropyrimidine dehydrogenase deficiency&#xD;
&#xD;
               -  Known hypersensitivity to 5-FU/capecitabine&#xD;
&#xD;
               -  Known positive test for human immunodeficiency virus (HIV), hepatitis C, or&#xD;
                  hepatitis B surface antigen&#xD;
&#xD;
               -  Known active or chronic hepatitis&#xD;
&#xD;
          -  Medications&#xD;
&#xD;
               -  Currently or previously treated with angiopoietin inhibitors, or inhibitors of&#xD;
                  TIE-1 or TIE-2&#xD;
&#xD;
               -  Treatment with immune modulators such as cyclosporine or tacrolimus within 30&#xD;
                  days prior to randomization&#xD;
&#xD;
               -  Treatment with sorivudine or its chemically related analogues&#xD;
&#xD;
               -  Anticoagulants (other than aspirin and anti-platelet agents) within 7 days prior&#xD;
                  to randomization. The concurrent use of low molecular weight heparin or&#xD;
                  heparanoids or low dose warfarin (i.e, ≤ 1 mg daily) for prophylaxis against&#xD;
                  thrombosis is acceptable while on study&#xD;
&#xD;
          -  General&#xD;
&#xD;
               -  Not yet completed at least 30 days since ending other investigational device/drug&#xD;
                  trial(s), or subject is receiving other investigational treatments&#xD;
&#xD;
               -  Pregnant or is breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Valladares-Ayerbes M, Swieboda-Sadlej A, Van Cutsem E, Nanayakkara N, Sun YN, Zhong ZD, Bass MB, Adewoye AH, Bodoky G. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol. 2013 Mar;24(3):710-8. doi: 10.1093/annonc/mds502. Epub 2012 Oct 28.</citation>
    <PMID>23108953</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <disposition_first_submitted>February 7, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>February 7, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 11, 2014</disposition_first_posted>
  <last_update_submitted>April 21, 2014</last_update_submitted>
  <last_update_submitted_qc>April 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma</keyword>
  <keyword>AMG 386</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trebananib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

